Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Overview
Chronic kidney disease (CKD) is the damage to kidneys wherein it cannot filter blood the way they are supposed to. This is a chronic disease since the damage to kidneys can happen slowly over a long period of time. CKD can lead to other health problems as well. The global chronic kidney disease (CKD) drugs market focuses on six regions namely North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The global chronic kidney disease (CKD) drug market is expected to witness significant growth during the forecast period, owing to rising geriatric population worldwide.
Market Driver
Rising prevalence of chronic kidney disease is expected to drive growth of the global chronic kidney disease (CKD) drugs market during the forecast period. CKD has become prevalent in the recent past in both developed and emerging economies. According to the National Kidney Foundation, around 80 million U.S. citizens are at risk of CKD and is more common in women than men. According to the same source, in 2017, over 200,000 people received kidney transplants. As a result of this, the demand for CKD drugs has increased. Thus, these factors are expected to drive growth of the global chronic kidney disease (CKD) drugs market during the forecast period. Furthermore, rising geriatric population is expected to propel the global chronic kidney disease (CKD) drugs market growth over the forecast period.
Market Restraint
Rising use of generic drugs is expected to hamper the global chronic kidney disease (CKD) drugs market growth over the forecast period.
Regional Insights
Among regions, North America is expected to witness significant growth in the global chronic kidney disease (CKD) drugs market during the forecast period. This is owing to presence of major pharmaceutical companies across the regions. Moreover, Asia Pacific is expected to register a lucrative growth rate over the forecast period, owing to increasing incidence of diabetes and hypertension across the region.
Competitive Section
Major companies operating in the global chronic kidney disease (CKD) drugs market are AbbVie, Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Allergan plc, GlaxoSmithKline plc, AstraZeneca plc., Johnson & Johnson, and Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and Sanofi S.A.
Major market players are focused on research and development activities, in order to enhance the market presence. For instance, in October 2018, GlaxoSmithKline plc (GSK) announced positive results for phase 3 daprodustat in patients with anemia associated with chronic kidney disease.
Key features of the study:
- This report provides in-depth analysis of chronic kidney disease drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global chronic kidney disease drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the chronic kidney disease drugs market
Detailed Segmentation:
• Global Chronic Kidney Disease Drugs Market, By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
• Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Chronic Kidney Disease Drugs Market, By Region:
o North America
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o U.S.
o Canada
o Europe
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o Brazil
o Mexico
o Rest of Latin America
o Middle East
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o GCC
o Israel
o Rest of Middle East
o Africa
o By Drug Class:
o ACE Inhibitors
o B-Blockers
o Calcium Channel Blockers
o Diuretics
o Erythropoiesis-Stimulating Agents (ESAs)
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o By Country:
o Central Africa
o South Africa
o North Africa
• Company Profiles
o Amgen, Inc.*
o Company Overview
o Product Portfolio
o Financial Performance
o Key Strategies
o Recent Developments
o Teva Pharmaceutical Industries Ltd.
o Pfizer, Inc.
o AstraZeneca Plc
o F. Hoffmann La Roche Ltd.
o Sanofi S.A.
o Kissei Pharmaceutical Co. Ltd.
o AbbVie Inc.
o GlaxoSmithKline Plc
o Keryx Biopharmaceuticals, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Class
o Market Snippet, By Distribution Channel
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o PEST Analysis
o PORTER's Analysis
o Regulatory Scenario
4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o ACE Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o B-Blockers
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Calcium Channel Blockers
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Diuretics
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Erythropoiesis-Stimulating Agents (ESAs)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
5. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2016-2026
o Segment Trends
o Hospital Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
6. Global Chronic Kidney Disease Drugs Market, By Regions, 2016-2026 (US$ Mn)
o Introduction
o Market Share Analysis, By Region, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o U.S.
o Canada
o Europe
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of APAC
o Latin America
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o Central Africa
o South Africa
o North Africa
o Middle East
o Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
o Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
o GCC
o Israel
o Rest of Middle East
7. Competitive Landscape
o Company Profiles
o Amgen, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Pfizer, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o AstraZeneca Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o F. Hoffman La Roche Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Sanofi S.A.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Kissei Pharmaceutical Co. Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o AbbVie, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o GlaxoSmithKline Plc
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Keryx Biopharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
8. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 29 market data tables and 47 figures on "Chronic Kidney Disease Drugs Market - Global forecast to 2026".
